Tempus AI, Inc. (NASDAQ:TEM) Receives $69.33 Average Target Price from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received a consensus rating of “Hold” from the twenty-two brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $69.6316.

TEM has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on Tempus AI in a research report on Monday. They set a “neutral” rating and a $75.00 target price on the stock. Guggenheim raised their price objective on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 11th. Rothschild & Co Redburn began coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. Finally, Raymond James Financial set a $80.00 target price on shares of Tempus AI in a research note on Wednesday, September 2nd.

Insider Buying and Selling

In other Tempus AI news, CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the sale, the chief executive officer directly owned 200,000 shares of the company’s stock, valued at approximately $8,412,000. This represents a 55.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the sale, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. This trade represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 1,254,701 shares of company stock worth $73,877,392. 24.26% of the stock is owned by insiders.

Institutional Trading of Tempus AI

Hedge funds have recently bought and sold shares of the business. Eagle Health Investments LP purchased a new stake in shares of Tempus AI during the 1st quarter valued at $11,588,000. Alethea Capital Management LLC purchased a new position in shares of Tempus AI in the 4th quarter worth about $1,863,000. Aristotle Atlantic Partners LLC purchased a new position in shares of Tempus AI in the 1st quarter worth about $6,179,000. Headlands Technologies LLC bought a new position in Tempus AI during the second quarter valued at about $2,689,000. Finally, Lingotto Investment Management LLP increased its holdings in Tempus AI by 45.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock worth $67,525,000 after buying an additional 359,667 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Whole-genome platform expands growth narrative: Tempus AI launched a research platform based on 100,000 genomes, with plans to scale toward 1 million genomes. The initiative could strengthen the company’s data advantage and support future AI-driven drug discovery and precision-medicine products. Tempus AI Is Up 31.9% After Launching 100,000-Genome AI Research Platform Initiative Tempus AI Unveils Whole Genome Platform With Plans For 1 Million Genomes
• Positive Sentiment: ARPA-H contract adds validation: Tempus secured up to $9.5 million from the U.S. health research agency ARPA-H to develop an autonomous AI agent for heart-failure care. Although the award is modest relative to Tempus’s revenue base, it provides government-backed validation of the company’s healthcare AI technology and creates a potential future commercialization opportunity. Tempus Secures Up To $9.5 Million From ARPA-H
• Neutral Sentiment: Goldman Sachs begins coverage: Goldman Sachs initiated Tempus AI at Neutral with a $75 price target. The rating suggests the firm sees limited near-term upside after the recent rally and is seeking clearer evidence that Tempus’s growth initiatives justify its valuation. Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target
• Negative Sentiment: Valuation concerns remain: A bearish analysis argues that the market is pricing Tempus AI on uncertain future outcomes rather than established earnings, increasing downside risk if growth or monetization fails to meet expectations. Tempus AI: Market Is Hyping On An Uncertain Number
• Negative Sentiment: Multiple insiders reported stock sales: The CEO sold approximately $16.1 million of shares, while the chief accounting officer and an executive vice president sold roughly $529,650 and $221,325, respectively. Additional CEO selling was also reported. These transactions may weigh on sentiment by signaling that insiders are taking advantage of elevated prices, although they do not necessarily indicate a change in business fundamentals.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $78.03 on Thursday. The stock has a market cap of $14.08 billion, a price-to-earnings ratio of -54.19 and a beta of 3.72. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The firm’s 50-day simple moving average is $57.63 and its 200 day simple moving average is $53.09.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period in the previous year, the company posted ($0.22) EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, research analysts anticipate that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.